Physician profile
Frederick Brandt
NPI 1528008737
$9,580.37
in general payments reported to CMS, 2019-2025
21 companies · $916 in 2025
The $916 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,907 · 2020: $1,195 · 2021: $1,673 · 2022: $1,668 · 2023: $1,270 · 2024: $952 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Education: $46.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.43 |
| Education | $46.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,137.89 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Pfizer INC. | $1,632.60 | 2019-2025 | |
| Amgen INC. | $1,451.45 | 2019-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $852.12 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $466.37 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $379.96 | 2019-2023 | |
| Lilly USA, LLC | $327.99 | 2019-2024 | Taltz |
| Ucb, INC. | $314.11 | 2019-2025 | Bimzelx |
| Horizon Therapeutics Plc | $208.94 | 2021-2022 | |
| Genentech USA, INC. | $170.91 | 2019-2020 | |
| Glaxosmithkline, LLC. | $166.07 | 2019-2023 | Benlysta |
| Genzyme Corporation | $115.16 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $92.62 | 2021-2025 | Lupkynis |
| Ferring Pharmaceuticals INC. | $66.92 | 2019 | |
| Celltrion USA INC. | $46.46 | 2023 | Yuflyma |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $44.20 | 2022 | |
| Depuy Synthes Sales INC. | $33.83 | 2019 | |
| Lundbeck LLC | $30.00 | 2024 | Vyepti |
| Ani Pharmaceuticals, INC. | $17.90 | 2024 | Purified Cortrophin Gel |
| Tonix Medicines, INC. | $13.49 | 2025 | Tonmya |
| Medexus Pharma, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Brandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.